SeaStar Medical Adds Second Hospital Customer for QUELIMMUNE
31. Oktober 2024 08:30 ET
|
SeaStar Medical Holding Corporation
DENVER, Oct. 31, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage medical device company developing proprietary solutions to reduce the consequences of...
SeaStar Medical Strengthens Financial Position with Elimination of All Long-Term Debt
04. September 2024 08:30 ET
|
SeaStar Medical Holding Corporation
DENVER, Sept. 04, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU) (SeaStar Medical), a commercial-stage medical device company developing proprietary solutions to reduce...
First Pediatric Patient Treated in a Commercial Setting with SeaStar Medical’s FDA-Approved QUELIMMUNE Therapeutic Device
23. Juli 2024 08:30 ET
|
SeaStar Medical Holding Corporation
DENVER, July 23, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU) (SeaStar Medical) reports treatment of the first patient in a commercial setting with QUELIMMUNE™, its...
SeaStar Medical Finalizes FDA Labeling Requirement for QUELIMMUNE, Paving the Way for First Commercial Sales as Humanitarian Use Device
03. Juli 2024 08:30 ET
|
SeaStar Medical Holding Corporation
DENVER, July 03, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage medical device company developing proprietary solutions to reduce the consequences of...
SeaStar Medical to Present at the Virtual Emerging Growth Conference on June 12, 2024
06. Juni 2024 16:05 ET
|
SeaStar Medical Holding Corporation
DENVER, June 06, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage medical device company developing proprietary solutions to reduce the consequences of...
SeaStar Medical Reports First Quarter 2024 Financial Results and Provides a Business Update
14. Mai 2024 16:05 ET
|
SeaStar Medical Holding Corporation
DENVER, May 14, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU) (“SeaStar Medical” or the “Company”), a commercial-stage medical device company developing proprietary...
SeaStar Medical Updates Subject Enrollment in its Pivotal Trial with the Selective Cytopheretic Device in Adults with Acute Kidney Injury
28. Dezember 2023 08:30 ET
|
SeaStar Medical Holding Corporation
DENVER, Dec. 28, 2023 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a medical device company developing proprietary solutions to reduce the consequences of hyperinflammation...
SeaStar Medical Reports Third Quarter 2023 Financial Results and Provides a Business Update
14. November 2023 16:04 ET
|
SeaStar Medical Holding Corporation
DENVER, Nov. 14, 2023 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU) (“SeaStar Medical” or the “Company”), a medical device company developing proprietary solutions to reduce...
FDA Issues Approvable Letter for SeaStar Medical’s Selective Cytopheretic Device for Pediatric Patients
30. Oktober 2023 08:00 ET
|
SeaStar Medical Holding Corporation
DENVER, Oct. 30, 2023 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a medical device company developing proprietary solutions to reduce the consequences of dysregulated...
SeaStar Medical to Present at the Dawson James Small Cap Growth Conference on October 12, 2023
05. Oktober 2023 08:30 ET
|
SeaStar Medical Holding Corporation
DENVER, Oct. 05, 2023 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a medical device company developing proprietary solutions to reduce the consequences of hyperinflammation...